In those types of cancer, MARCH5 may act as a tumor suppressor by inhibiting MCL1 overexpression, and a therapeutic strategy involving the use of BH3 mimetics could be paired with MARCH5 induction, in order to achieve cancer regression (Figure 1). Here, MCL1 is linked to neoplasm.